New insights in endometrial carcinogenesis

Journal of Cellular Physiology

Volumn 227, Issue 7, 2012, Pages 2842-2846

  D'Andrilli, Giuseppina ^a   Bovicelli, Alessandro ^a,b   Paggi, Marco G ^a,c   Giordano, Antonio ^a,d  

^a Temple University   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; ENDOGLIN; ESTROGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P105; PROTEIN P107; PROTEIN P130; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; RING FINGER PROTEIN; SURVIVIN; TAMOXIFEN; VASCULOTROPIN;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; DOWN REGULATION; DRUG TARGETING; ENDOMETRIUM CARCINOGENESIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE INFERTILITY; GENE MUTATION; HUMAN; HYSTERECTOMY; IMMUNOREACTIVITY; MISMATCH REPAIR; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UTERUS BLEEDING; VAGINA BLEEDING;

ADENOCARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858676928     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24016     Document Type: Review

References (33)

1. Abd El-Maqsoud NM, El-Gelany S. 2009. Differential expression patterns of PTEN in cyclic, hyperplastic and malignant endometrium: Its relation with ER, PR and clinicopathological parameters. J Egypt Natl Canc Inst 21: 323-331.
2. Bermont L, Lamielle F, Lorchel F, Fauconnet S, Esumi H, Weisz A, Adessi GL. 2001. Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. J Clin Endocrinol Metab 86: 363-368.
3. Boruban MC, Altundag K, Kilic GS, Blankstein J. 2008. From endometrial hyperplasia to endometrial cancer: Insight into the biology and possible medical preventive measures. Eur J Cancer Prev 17: 133-138.
4. Bovicelli A, D'Andrilli G, Giordano A. 2011. New players in ovarian cancer. J Cell Physiol 226: 2500-2504.
5. Brucka A, Bartczak P, Ratynska M, Sporny S. 2009. Immunohistochemical pattern of protein P21, cyclin D1 and cyclin E in endometrial hyperplasia. Pol J Pathol 60: 19-25.
6. Buchynska LG, Nesina IP, Kashuba EV. 2007. Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia. Exp Oncol 29: 287-294.
7. Chen J, Li S, Yang Z, Lu G, Hu H. 2008. Correlation between NDRG1 and PTEN expression in endometrial carcinoma. Cancer Sci 99: 706-710.
8. Chien W, Kumagai T, Miller CW, Desmond JC, Frank JM, Said JW, Koeffler HP. 2004. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 279: 53087-53096.
9. Dai H, Zhao S, Xu L, Chen A, Dai S. 2010. Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue. Oncol Rep 23: 795-799.
10. Erdem O, Erdem M, Erdem A, Memis L, Akyol G. 2007. Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma. Int J Gynecol Cancer 17: 1327-1332.
11. Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F, Haberal A, Demirhan B. 2006. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer 16: 1412-1418.
12. Farhi DC, Nosanchuk J, Silverberg SG. 1986. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 68: 741-745.
13. Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, Suzuki A, Konishi I. 2005. BRAF mutation in endometrial carcinoma and hyperplasia: Correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 11: 6133-6138.
14. Gallup DG, Stock RJ. 1984. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 64: 417-420.
15. Guida M, Sanguedolce F, Bufo P, Di Spiezio Sardo A, Bifulco G, Nappi C, Pannone G. 2009. Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol 30: 267-270.
16. Janiec-Jankowska A, Konopka B, Goluda C, Najmola U. 2010. TP53 mutations in endometrial cancers: Relation to PTEN gene defects. Int J Gynecol Cancer 20: 196-202.
17. Lax SF. 2004. Molecular genetic pathways in various types of endometrial carcinoma: From a phenotypical to a molecular-based classification. Virchows Arch 444: 213-223.
18. Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. 2010. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: A clinicopathologic study of 131 cases and literature review. Gynecol Oncol 116: 533-538.
19. Masciullo V, Susini T, Zamparelli A, Bovicelli A, Minimo C, Massi D, Taddei G, Maggiano N, De Iaco P, Ceccaroni M, Bovicelli L, Amunni G, Mancuso S, Scambia G, Giordano A. 2003. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(kip1) in estrogen-related Endometrial adenocarcinomas. Clin Cancer Res 9: 5332-5338.
20. Masciullo V, Amadio G, Lo Russo D, Raimondo I, Giordano A, Scambia G. 2010. Controversies in the management of endometrial cancer. Obstet Gynecol Int 2010: 638165.
21. Mills AM, Longacre TA. 2010. Endometrial hyperplasia. Semin Diagn Pathol 27: 199-214.
22. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. 2000. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924-930.
23. Nunobiki O, Nakamura M, Taniguchi E, Utsunomiya H, Mori I, Tsubota Y, Mabuchi Y, Kakudo K. 2009. Adrenomedullin, Bcl-2 and microvessel density in normal, hyperplastic and neoplastic endometrium. Pathol Int 59: 530-536.
24. Nyholm HC, Nielsen AL, Norup P. 1993. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: Comparison of clinical and histopathological characteristics. Gynecol Oncol 49: 229-235.
25. Ozkara SK, Corakci A. 2004. Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression). Pathol Oncol Res 10: 89-97.
26. Rao AC, Arya G, Padma PJ. 2011. Immunohistochemical phospho tensin tumor suppressor gene staining patterns in endometrial hyperplasias: A 2-year study. Indian J Pathol Microbiol 54: 264-268.
27. Sanseverino F, Torricelli M, Petraglia F, Giordano A. 2003. Role of the retinoblastoma family in gynecological cancer. Cancer Biol Ther 2: 636-641.
28. Sanseverino F, Santopietro R, Torricelli M, D'Andrilli G, Russo G, Cevenini G, Bovicelli A, Leoncini L, Scambia G, Petraglia F, Claudio PP, Giordano A. 2006. pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol Ther 5: 84-88.
29. Sarmadi S, Izadi-Mood N, Sotoudeh K, Tavangar SM. 2009. Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol 4: 41.
30. Susini T, Baldi F, Howard CM, Baldi A, Taddei G, Massi D, Rapi S, Savino L, Massi G, Giordano A. 1998. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J Clin Oncol 16: 1085-1093.
31. Susini T, Massi D, Paglierani M, Masciullo V, Scambia G, Giordano A, Amunni G, Massi G, Taddei GL. 2001. Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma. Hum Pathol 32: 360-367.
32. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S. 2008. Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. J Med Assoc Thai 91: 1161-1165.
33. Watanabe J, Nishizaki R, Jobo T, Kamata Y, Hata H, Nishimura Y, Fujisawa T, Okayasu I, Kuramoto H. 2004. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus. Int J Gynecol Pathol 23: 234-240.